DNA Damage Using hERY-MNT Technology can Predict Chemotherapy Induced Toxicity in Women with Ovarian Cancer

Overview

About this study

The purpose of this study is to understand changes that take place in the blood of patients with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This portion of the study is to understand the changes that occur in your blood during and after treatment with carboplatin and paclitaxel chemotherapy in women with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Over age 18
Histologically confirmed ovarian, primary peritoneal or fallopian tube cancer
For Aim 2 only:
- No prior chemotherapy for ovarian cancer
- Chemotherapy in the form of carboplatin and paclitaxel

Exclusion Criteria:

Prior hematologic malignancy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Andrea Wahner Hendrickson, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Andrea Wahner Hendrickson, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials